AAA+ proteins, a superfamily of ATPases associated with diverse cellular activities, play essential roles in energy-dependent remodeling of macromolecular complexes such as proteins, DNA, and RNA. Their function hinges on a conserved 250-amino acid AAA+ domain that typically forms oligomeric structures critical for processes including protein quality control, DNA replication, and cytoskeletal dynamics. Dysregulation of these molecular machines is linked to severe human pathologies, including neurodegenerative diseases and cancer progression. Despite their biological significance, therapeutic targeting of AAA+ proteins has remained challenging due to the high structural conservation across the family, dynamic conformational changes during catalysis, and the hydrophilic nature of their ATP-binding sites.
Traditional drug discovery efforts relying on broad-spectrum compound screens have yielded only a limited number of inhibitors with poor selectivity. Inhibitors binding allosteric sites may disrupt complex assembly or protein stability, leading to off-target effects. Moreover, the scarcity of high-resolution structures for many AAA+ complexes hampers rational design. Targeting the ATP-binding site using competitive nucleotide analogs offers a promising alternative—providing potential for both specificity and cross-family applicability. However, achieving this remains difficult because of sequence conservation and conformational flexibility in the active site.
Recently, Tarun Kapoor’s group pioneered a chemical genetics strategy known as RADD (Resistance Analysis During Design), which enables the development of selective inhibitors by exploiting subtle differences in the ATP-binding pocket. The approach identifies a “variability hotspot”—a cluster of four amino acids in the active site whose mutation can alter inhibitor sensitivity without affecting enzymatic activity. By introducing silent mutations at these positions, researchers can screen for compounds that bind the wild-type site but not the mutated one, thereby identifying highly specific ligands.CD30 Antibody In stock
In a recent study, Cupido et al.CD116 Antibody In stock extended this concept to katanin, a microtubule-severing AAA+ complex.PMID:34996900 Instead of starting with an inhibitor, they first engineered a katanin variant with a strategically placed cysteine residue—a “bump-and-hole” modification—without compromising function. This allowed them to design ASPIR-1, a covalent, nucleotide-competitive inhibitor that selectively binds the mutant enzyme with subnanomolar potency (<50 nM). Upon exposure to ASPIR-1, cells exhibited phenotypes identical to those seen after genetic depletion of katanin, confirming rapid and specific inhibition in vivo. Crucially, the same inhibitor was shown to effectively target homologous AAA+ proteins involved in membrane remodeling (VPS4B) and DNA repair (FIGL1), suggesting a shared binding mode across the superfamily. This opens the door to creating analogous inhibitor-sensitive variants in other AAA+ proteins simply by introducing a cysteine at the equivalent position. This work establishes a powerful platform for dissecting the functional roles of individual AAA+ isoforms, transient protein complexes, and disease-causing mutations in real time. It also provides a robust method for detecting off-target effects during drug development and accelerates the creation of precision therapeutics. With its cost-efficiency and scalability, the RADD-based approach holds significant promise for treating rare diseases caused by ATP-pocket mutations through protein-stabilizing drugs.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com